Lundbeck plans to refocus and reinvigorate Research & Development
As part of its Expand and Invest to Grow-strategy, Lundbeck plans to make changes to its organization in Research & Development (R&D). The initiative could lead to a reduction of around 130-160 positions (subject to consultation).
H. Lundbeck A/S (Lundbeck) plans to optimize its R&D-organization to enhance the company’s ability to strengthen and advance its pipeline across all phases in an evolving neuroscience landscape.
The plan follows Lundbeck’s Expand and Invest to Grow-strategy of expanding the company’s operating space and rebuilding its pipeline of potential new medicines to treat brain disorders. Key elements include focusing Lundbeck’s R&D efforts where the science is most promising and on biological platforms were Lundbeck can have world class expertise. Lundbeck will also strengthen competencies to leverage new technologies and will build agility and flexibility into its ways of working in order to lead in the ever-evolving neuroscience landscape.
“The proposed changes will allow us to fully execute on our strategy in the years to come and rebuild our pipeline with innovative programs with strong potential to deliver highly impactful treatments for patients with brain disorders. Through this we will support Lundbeck in becoming the premier neuroscience company, globally” says Johan Luthman, Executive Vice President, R&D at Lundbeck.
If the changes are carried through, it may lead to a reduction of 130-160 positions globally, including approximately 100 in Denmark. Lundbeck has informed the company’s Works Council and its European Works Council about the restructuring plans.
Mikkel Ballegaard Pedersen
|Journalist, Corp. Communication||Senior Director, Corp. Communication|
|+45 30 83 20 44||+45 36 43 40 00|
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and the US and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.0 billion in 2019 (EUR 2.3 billion; USD 2.6 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.